(FTV) Fortive - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US34959J1088
Stock: Industrial Software, Healthcare Technology, Measurement Tools
Total Rating 46
Risk 77
Buy Signal 0.02
| Risk 5d forecast | |
|---|---|
| Volatility | 24.3% |
| Relative Tail Risk | -8.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -22.57 |
| Character TTM | |
|---|---|
| Beta | 1.040 |
| Beta Downside | 1.299 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.01% |
| CAGR/Max DD | 0.20 |
EPS (Earnings per Share)
Revenue
Description: FTV Fortive March 05, 2026
Fortive Corporation (FTV) designs and manufactures professional technical equipment and software. It operates in the Industrial Machinery & Supplies & Components sector, which is characterized by specialized product offerings and business-to-business sales models.
The company has two segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. The Intelligent Operating Solutions segment provides instrumentation, software, and services for various industries, including manufacturing and healthcare. This segments products often involve high switching costs for customers due to integration with existing systems.
The Advanced Healthcare Solutions segment offers critical workflow solutions for healthcare, such as instrument sterilization and clinical productivity software. Healthcare technology companies benefit from recurring revenue streams through service contracts and software subscriptions.
Further research on ValueRay can provide deeper insights into Fortives financial performance and market position.
Headlines to watch out for
- Industrial demand for intelligent operating solutions drives revenue
- Healthcare capital expenditure impacts advanced healthcare sales
- Software and services subscriptions provide recurring revenue
- Global supply chain disruptions increase manufacturing costs
- Regulatory changes in healthcare affect product development
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 579.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: -12.46% < 20% (prev 5.68%; Δ -18.14% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.08b > Net Income 579.2m |
| Net Debt (2.83b) to EBITDA (1.17b): 2.42 < 3 |
| Current Ratio: 0.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (319.4m) vs 12m ago -8.22% < -2% |
| Gross Margin: 60.96% > 18% (prev 0.60%; Δ 6.04k% > 0.5%) |
| Asset Turnover: 35.77% > 50% (prev 36.62%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: 5.13 > 6 (EBITDA TTM 1.17b / Interest Expense TTM 120.5m) |
Altman Z'' 2.53
| A: -0.05 (Total Current Assets 1.61b - Total Current Liabilities 2.25b) / Total Assets 11.74b |
| B: 0.46 (Retained Earnings 5.43b / Total Assets 11.74b) |
| C: 0.04 (EBIT TTM 617.9m / Avg Total Assets 14.38b) |
| D: 1.04 (Book Value of Equity 5.47b / Total Liabilities 5.28b) |
| Altman-Z'' Score: 2.53 = A |
Beneish M -3.30
| DSRI: 0.88 (Receivables 683.6m/945.4m, Revenue 5.14b/6.23b) |
| GMI: 0.98 (GM 60.96% / 59.87%) |
| AQI: 1.02 (AQ_t 0.84 / AQ_t-1 0.82) |
| SGI: 0.83 (Revenue 5.14b / 6.23b) |
| TATA: -0.04 (NI 579.2m - CFO 1.08b) / TA 11.74b) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of FTV shares?
As of March 14, 2026, the stock is trading at USD 56.31 with a total of 3,074,689 shares traded.
Over the past week, the price has changed by -5.33%, over one month by -4.52%, over three months by -1.84% and over the past year by +0.87%.
Over the past week, the price has changed by -5.33%, over one month by -4.52%, over three months by -1.84% and over the past year by +0.87%.
Is FTV a buy, sell or hold?
Fortive has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy FTV.
- StrongBuy: 6
- Buy: 5
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FTV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 10.4% |
| Analysts Target Price | 62.2 | 10.4% |
FTV Fundamental Data Overview March 10, 2026
P/E Trailing = 36.0943
P/E Forward = 19.6464
P/S = 4.3826
P/B = 2.7378
P/EG = 0.9827
Revenue TTM = 5.14b USD
EBIT TTM = 617.9m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 899.5m USD (from shortTermDebt, last quarter)
Debt = 3.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.83b USD (from netDebt column, last quarter)
Enterprise Value = 21.06b USD (18.23b + Debt 3.21b - CCE 375.5m)
Interest Coverage Ratio = 5.13 (Ebit TTM 617.9m / Interest Expense TTM 120.5m)
EV/FCF = 21.53x (Enterprise Value 21.06b / FCF TTM 978.1m)
FCF Yield = 4.64% (FCF TTM 978.1m / Enterprise Value 21.06b)
FCF Margin = 19.02% (FCF TTM 978.1m / Revenue TTM 5.14b)
Net Margin = 11.26% (Net Income TTM 579.2m / Revenue TTM 5.14b)
Gross Margin = 60.96% ((Revenue TTM 5.14b - Cost of Revenue TTM 2.01b) / Revenue TTM)
Gross Margin QoQ = 63.15% (prev 63.21%)
Tobins Q-Ratio = 1.79 (Enterprise Value 21.06b / Total Assets 11.74b)
Interest Expense / Debt = 0.97% (Interest Expense 31.0m / Debt 3.21b)
Taxrate = 1.24% (2.40m / 193.9m)
NOPAT = 610.3m (EBIT 617.9m * (1 - 1.24%))
Current Ratio = 0.71 (Total Current Assets 1.61b / Total Current Liabilities 2.25b)
Debt / Equity = 0.50 (Debt 3.21b / totalStockholderEquity, last quarter 6.45b)
Debt / EBITDA = 2.42 (Net Debt 2.83b / EBITDA 1.17b)
Debt / FCF = 2.89 (Net Debt 2.83b / FCF TTM 978.1m)
Total Stockholder Equity = 8.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.03% (Net Income 579.2m / Total Assets 11.74b)
RoE = 6.90% (Net Income TTM 579.2m / Total Stockholder Equity 8.39b)
RoCE = 5.77% (EBIT 617.9m / Capital Employed (Equity 8.39b + L.T.Debt 2.31b))
RoIC = 5.01% (NOPAT 610.3m / Invested Capital 12.19b)
WACC = 8.43% (E(18.23b)/V(21.43b) * Re(9.75%) + D(3.21b)/V(21.43b) * Rd(0.97%) * (1-Tc(0.01)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.08%
[DCF] Terminal Value 77.64% ; FCFF base≈1.15b ; Y1≈1.24b ; Y5≈1.52b
[DCF] Fair Price = 69.89 (EV 24.35b - Net Debt 2.83b = Equity 21.52b / Shares 307.9m; r=8.43% [WACC]; 5y FCF grow 8.79% → 2.90% )
EPS Correlation: -30.64 | EPS CAGR: 6.93% | SUE: 1.35 | # QB: 1
Revenue Correlation: -38.58 | Revenue CAGR: -5.29% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.69 | Chg7d=+0.001 | Chg30d=+0.008 | Revisions Net=+4 | Analysts=15
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.001 | Chg30d=+0.119 | Revisions Net=+14 | Growth EPS=+9.4% | Growth Revenue=+3.8%
EPS next Year (2027-12-31): EPS=3.18 | Chg7d=+0.002 | Chg30d=+0.139 | Revisions Net=+9 | Growth EPS=+7.3% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.0% (Discount Rate 9.8% - Earnings Yield 2.8%)
[Growth] Growth Spread = -2.4% (Analyst 4.6% - Implied 7.0%)
P/E Forward = 19.6464
P/S = 4.3826
P/B = 2.7378
P/EG = 0.9827
Revenue TTM = 5.14b USD
EBIT TTM = 617.9m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 899.5m USD (from shortTermDebt, last quarter)
Debt = 3.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.83b USD (from netDebt column, last quarter)
Enterprise Value = 21.06b USD (18.23b + Debt 3.21b - CCE 375.5m)
Interest Coverage Ratio = 5.13 (Ebit TTM 617.9m / Interest Expense TTM 120.5m)
EV/FCF = 21.53x (Enterprise Value 21.06b / FCF TTM 978.1m)
FCF Yield = 4.64% (FCF TTM 978.1m / Enterprise Value 21.06b)
FCF Margin = 19.02% (FCF TTM 978.1m / Revenue TTM 5.14b)
Net Margin = 11.26% (Net Income TTM 579.2m / Revenue TTM 5.14b)
Gross Margin = 60.96% ((Revenue TTM 5.14b - Cost of Revenue TTM 2.01b) / Revenue TTM)
Gross Margin QoQ = 63.15% (prev 63.21%)
Tobins Q-Ratio = 1.79 (Enterprise Value 21.06b / Total Assets 11.74b)
Interest Expense / Debt = 0.97% (Interest Expense 31.0m / Debt 3.21b)
Taxrate = 1.24% (2.40m / 193.9m)
NOPAT = 610.3m (EBIT 617.9m * (1 - 1.24%))
Current Ratio = 0.71 (Total Current Assets 1.61b / Total Current Liabilities 2.25b)
Debt / Equity = 0.50 (Debt 3.21b / totalStockholderEquity, last quarter 6.45b)
Debt / EBITDA = 2.42 (Net Debt 2.83b / EBITDA 1.17b)
Debt / FCF = 2.89 (Net Debt 2.83b / FCF TTM 978.1m)
Total Stockholder Equity = 8.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.03% (Net Income 579.2m / Total Assets 11.74b)
RoE = 6.90% (Net Income TTM 579.2m / Total Stockholder Equity 8.39b)
RoCE = 5.77% (EBIT 617.9m / Capital Employed (Equity 8.39b + L.T.Debt 2.31b))
RoIC = 5.01% (NOPAT 610.3m / Invested Capital 12.19b)
WACC = 8.43% (E(18.23b)/V(21.43b) * Re(9.75%) + D(3.21b)/V(21.43b) * Rd(0.97%) * (1-Tc(0.01)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.08%
[DCF] Terminal Value 77.64% ; FCFF base≈1.15b ; Y1≈1.24b ; Y5≈1.52b
[DCF] Fair Price = 69.89 (EV 24.35b - Net Debt 2.83b = Equity 21.52b / Shares 307.9m; r=8.43% [WACC]; 5y FCF grow 8.79% → 2.90% )
EPS Correlation: -30.64 | EPS CAGR: 6.93% | SUE: 1.35 | # QB: 1
Revenue Correlation: -38.58 | Revenue CAGR: -5.29% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.69 | Chg7d=+0.001 | Chg30d=+0.008 | Revisions Net=+4 | Analysts=15
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.001 | Chg30d=+0.119 | Revisions Net=+14 | Growth EPS=+9.4% | Growth Revenue=+3.8%
EPS next Year (2027-12-31): EPS=3.18 | Chg7d=+0.002 | Chg30d=+0.139 | Revisions Net=+9 | Growth EPS=+7.3% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.0% (Discount Rate 9.8% - Earnings Yield 2.8%)
[Growth] Growth Spread = -2.4% (Analyst 4.6% - Implied 7.0%)